|
Schirdewan博士的引述的參考文獻:
+ o* e) P( q4 y1 u/ \5 Y& h5 a2 p0 O# C1 z5 x9 ?2 s) I" D
Camm, AJ et al., Remote control of implanted devices through Home Monitoring technology improves detection and clinical management of atrial fibrillation (透過Home Monitoring技術遠距控制植入式裝置可改進房顫的檢測和臨床管理), Europace, 11(1):54–61, 2009. + K# V: |) P( C& { Q1 |7 y
, v% N! S; P- H7 E9 V5 e; b- n& hDaubert, JP et al., Inappropriate implantable cardioverter-defibrillator shocks in MADIT-II (MADIT-II中植入式心臟複律去顫器不合時宜的電擊), JACC, 51:1357–65, 2008 7 H* O" D0 j$ c! U" I8 V# @
2 y! t+ q: w# \8 X9 L& PRicci, RP et al., Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) (心房顫動管理指南:歐洲心臟學會心房顫動管理工作小組), Europace, 12(10):1360–1420, 2010. 1 Y: S, D& r. z/ F) G5 K
' s( A- z; q# a% ]$ J6 h關於BIOTRONIK SE & Co. KG
! x; w4 U+ I. D* W+ O
5 {! v. \; ]5 i5 N. LBIOTRONIK公司是世界領先的心血管醫療器材製造商之一,已售出數百萬台植入式裝置,全球員工超過5600位,業務遍及100多個國家。BIOTRONIK公司密切感知醫療界的脈動、評估醫生面臨的挑戰,從診斷、治療到患者管理,為患者醫護的所有階段提供最佳解決方案。BIOTRONIK公司及其不斷成功的理念在於品質、創新和可靠性,從而為全球醫生及其患者帶來信心和安心。進一步資訊請瀏覽: www.biotronik.com |
|